The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
The multiple roles of microRNA-155 in oncogenesis
Open accessAbstract
The microRNA miR-155 is prominent in cancer biology. Among microRNAs that have been linked to cancer, it is the most commonly overexpressed in malignancies (PNAS 109:20047-20052, 2012). Since its discovery, miR-155 has been implicated in promoting cancers of the breast, lung, liver, and lymphatic system. As such, targeted therapies may prove beneficial to cancer treatment. This review discusses the important role of miR-155 in oncogenesis. It synthesizes information from ten recent papers on miR-155, and includes an analysis and discussion of its association with cancer, interactions with other miRNAs, mechanisms of action, and the most promising available treatment options.Current debates in the field include the importance of miRNAs in general and their utility as targets in preventing tumorigenesis (Blood 119:513-520, 2012). Most of the papers being reviewed here confirm the role of miR-155 in oncogenesis (EMBO Mol Med 1:288-295, 2009). While there is some controversy surrounding recent research that claims that miR-155 may display anti-oncogenic or pro-immunological benefits (Cell Rep 2:1697-1709, 2012), most research seems to point to the importance of anti-miRs, with anti-miR-155 in particular, for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Normal BRCA1 represses miR-155 expression via its association with HDAC2 [[20]].](/paper-figures/5c68990cef9543a4912550d29027a6c9/the-multiple-roles-of-microrna-155-in-oncogenesis-figure-1.jpg)
![Figure 2 The interplay of MiR-155 in inflammation and the Warburg effect of cancer [[16]].](/paper-figures/a910389778a04a9d8b1eaaa19e43de71/the-multiple-roles-of-microrna-155-in-oncogenesis-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
(2008) · doi:10.1038/nrg2290 · Cited by 5,199
Regulation of the Germinal Center Response by MicroRNA-155
Thai, T., Calado, D. P., Casola, S. S., Ansel, K. M., Xiao, C., Xue, Y., Murphy, A. J., Frendewey, D. A., Valenzuela, D. M., Kutok, J. L., et al. (2007) · Science · doi:10.1126/science.1141229 · Cited by 1,477
Inflammation and cancer: An ancient link with novel potentials
Hussain, S. P., & Harris, C. C. (2007) · International Journal of Cancer · doi:10.1002/ijc.23173 · Cited by 1,113
miR-155 gene: A typical multifunctional microRNA
Faraoni, I., Antonetti, F. R., Cardone, J., & Bonmassar, E. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.02.013 · Cited by 815
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways
Schetter, A. J., Heegaard, N. H. H., & Harris, C. C. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp272 · Cited by 671
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma
Babar, I., Cheng, C. J., Booth, C. J., Liang, X., Weidhaas, J. B., Saltzman, W. M., & Slack, F. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201516109 · Cited by 506
Epigenetic diet: impact on the epigenome and cancer
Hardy, T. M., & Tollefsbol, T. O. (2011) · Epigenomics · doi:10.2217/epi.11.71 · Cited by 416
Jiang, S., Zhang, L.-F., Zhang, H.-W., Hu, S. N., Lu, M.-H., Liang, S., Li, B., Li, Y., Li, D., Wang, E.-D., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.45 · Cited by 358
miR-155 : On the Crosstalk Between Inflammation and Cancer
Tili, E., Croce, C. M., & Michaille, J. (2009) · International Reviews of Immunology · doi:10.1080/08830180903093796 · Cited by 346
miR‐155: an ancient regulator of the immune system
Vigorito, E., Kohlhaas, S. L., Lu, D., & Leyland, R. (2013) · Immunological Reviews · doi:10.1111/imr.12057 · Cited by 296
Tili, E., Michaille, J., Adair, B., Alder, H., Limagne, E., Taccioli, C., Ferracin, M., Delmas, D., Latruffe, N., & Croce, C. M. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq143 · Cited by 275
Epigenetic targets of bioactive dietary components for cancer prevention and therapy
Meeran, S. M., Ahmed, A. A., & Tollefsbol, T. O. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0011-5 · Cited by 260
Landis‐Piwowar, K. R., Huo, C., Chen, D., Milacic, V., Shi, G., Chan, T. H., & Dou, Q. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4699 · Cited by 236
Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155
Chang, S., Wang, R., Akagi, K., Kim, K.-A., Martin, B. K., Cavallone, L., Haines, D. C., Basik, M., Mai, P., Poggi, E. A., et al. (2011) · Nature Medicine · doi:10.1038/nm.2459 · Cited by 232
Forrest, A. R. R., Kanamori-Katayama, M., Tomaru, Y., Lassmann, T., Ninomiya, N., Takahashi, Y., de Hoon, M. J. L., Kubosaki, A., Kaiho, A., Suzuki, M., et al. (2010) · Leukemia · doi:10.1038/leu.2009.246 · Cited by 223
Onco‐miR‐155 targets SHIP1 to promote TNFα‐dependent growth of B cell lymphomas
Pedersen, I. M., Otero, D. C., Kao, E., Miletic, A. V., Hother, C., Ralfkiaer, E. M., Rickert, R. C., Grønbæk, K., & David, M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900028 · Cited by 209
Linnstaedt, S. D., Gottwein, E., Skalsky, R. L., Luftig, M. A., & Cullen, B. R. (2010) · Journal of Virology · doi:10.1128/jvi.01248-10 · Cited by 189
Epistasis between MicroRNAs 155 and 146a during T Cell-Mediated Antitumor Immunity
Huffaker, T. B., Hu, R., Runtsch, M. C., Bake, E., Chen, X., Zhao, J. L., Round, J. L., Baltimore, D., & O’Connell, R. M. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.10.025 · Cited by 173
The role of microRNAs in cancer.
Stahlhut, C. E., & Slack, F. (2006) · PubMed Central · Cited by 153
Sandhu, S. K., Volinia, S., Costinean, S., Galasso, M., Neinast, R., Santhanam, R., Parthun, M. R., Perrotti, D., Marcucci, G., Garzon, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213764109 · Cited by 130
MicroRNA-155 Function in B Cells
Calame, K. L. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.010 · Cited by 120
Zonari, E., Pucci, F., Saini, M., Mazzieri, R., Politi, L. S., Gentner, B., & Naldini, L. (2013) · Blood · doi:10.1182/blood-2012-08-449306 · Cited by 120
Li, Y., Liu, L., & Tollefsbol, T. O. (2009) · The FASEB Journal · doi:10.1096/fj.09-149328 · Cited by 120
MiR-155 Is a Liposarcoma Oncogene That Targets Casein Kinase-1α and Enhances β-Catenin Signaling
Zhang, P., Bill, K., Liu, J., Young, E. D., Peng, T., Bolshakov, S. V., Hoffman, A., Song, Y., Demicco, E. G., Terrada, D. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3027 · Cited by 113
Prognostic Impact of MiR-155 in Non-Small Cell Lung Cancer Evaluated by in Situ Hybridization
Dønnem, T., Eklo, K., Berg, T., Sørbye, S. W., Lønvik, K., Al‐Saad, S., Al-Shibli, K. I., Andersen, S., Stenvold, H., Bremnes, R. M., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-6 · Cited by 106
MicroRNAs: an emerging science in cancer epigenetics
Kala, R., Peek, G. W., Hardy, T. M., & Tollefsbol, T. O. (2013) · Journal of Clinical Bioinformatics · doi:10.1186/2043-9113-3-6 · Cited by 91
Zhang, M., Zhou, X., Wang, B., Yung, B. C., Lee, L. J., Ghoshal, K., & Lee, R. J. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.03.020 · Cited by 87
Li, S., Chen, T., Zhong, Z., Wang, Y., Li, Y., & Zhao, X. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.779 · Cited by 82
miR-155 regulates HGAL expression and increases lymphoma cell motility
Dagan, L. N., Jiang, X., Bhatt, S., Cubedo, E., Rajewsky, K., & Lossos, I. S. (2011) · Blood · doi:10.1182/blood-2011-08-370536 · Cited by 72
Willimott, S., & Wagner, S. D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.285718 · Cited by 64
Shhh! Silencing by microRNA-155
Teng, G., & Papavasiliou, F. N. (2008) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2008.0209 · Cited by 64
Cited by
Sorted by citations
Cornel, A. M., Mimpen, I. L., & Nierkens, S. (2020) · Cancers · doi:10.3390/cancers12071760 · Cited by 501
miR-155: An Important Role in Inflammation Response
Hu, J., Huang, S., Liu, X., Zhang, Y., Wei, S., & Hu, X. (2022) · Journal of Immunology Research · doi:10.1155/2022/7437281 · Cited by 171
“Additionally, Higgs et al. [70] reviewed that miR-155 was a noncoding transcript expressed in activated B cells, T cells, monocytes, and macrophages.”
Anastasiadou, E., Seto, A. G., Beatty, X., Hermreck, M., Gilles, M.-E., Stroopinsky, D., Pinter‐Brown, L. C., Pestano, L. A., Marchese, C., Avigan, D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3139 · Cited by 163
Mitochondria-associated microRNAs in rat hippocampus following traumatic brain injury
Wang, W.-X., Visavadiya, N. P., Pandya, J. D., Nelson, P. T., Sullivan, P. G., & Springer, J. E. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2014.12.018 · Cited by 134
“The levels of miR-155 and miR-223, both of which play a role in several biological/ pathological processes including immunity, cancer, and inflammatory responses (Sonkoly et al., 2008; Quinn and O’Neill, 2011; Higgs and Slack, 2013; Vigorito et al., 2013; Seddiki et al., 2014; Taibi et al., 2014), were significantly e…”
Backgroundde la Parra, C., Castillo‐Pichardo, L., Cruz‐Collazo, A., Cubano, L. A., Redis, R. S., Călin, G. A., & Dharmawardhane, S. (2016) · Nutrition and Cancer · doi:10.1080/01635581.2016.1115104 · Cited by 133
Metadata
- Authors
- Higgs, G., & Slack, F.
- Affiliations
- Yale University (US)
- Corresponding author
- Higgs, Gadareth
- ORCID
- Slack, Frank
- Venue
- Journal of Clinical Bioinformatics
- Publisher
- ClinTransMed, AB
- Published
- 2013
- Volume
- 3
- Issue
- 1
- Pages
- 17
- ISSN
- 2043-9113 (ISSN-L)
- PMC
- PMC3849775
- OpenAlex
- W2128733367
- Cited by
- 137
- References
- 33
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 7 · 2023: 11 · 2022: 10 · 2021: 12 · 2020: 10 · 2019: 16 · 2018: 12 · 2017: 9 · 2016: 10 · 2015: 17 · 2014: 12
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Journal of Clinical Bioinformatics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Yale University
- Yale Cancer Center
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- miR-155, microRNA, carcinogenesis, cancer, anti-miR therapy, microRNA interactions, breast cancer, lung cancer, liver cancer, lymphoma, tumor immunology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
